Media Coverage

Back to Media Coverage

Fast-growing Cambridge biotech Sigilon inks $63M diabetes deal with Eli Lilly

The startup is developing what it calls “living therapeutics” — drugs based on engineered cells that can fight a range of disorders when implanted in the body.